MBRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses...

Stats
Today's Volume	3 871.00
Average Volume	86 036.00
Market Cap	11.03M
EPS	$0 ( 2024-05-10 )
Next earnings date	( $-2.10 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.370
ATR14	$0.105 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Foster Jonathan P.	Buy	28 986	Common Stock
2023-12-26	George Robert E.	Buy	14 493	Common Stock
2023-12-26	Klemp Walter V	Buy	188 404	Common Stock
2023-07-11	Klemp Walter V	Sell	13 204	Restricted Stock Units
2023-07-11	Klemp Walter V	Buy	13 204	Common Stock

INSIDER POWER
82.48
Last 98 transactions
Buy: 6 351 373 \| Sell: 471 392

Moleculin Biotech Inc Correlation

10 Most Positive Correlations
DHC	0.928
BIRD	0.911
AEHR	0.911
WKHS	0.909
VMAR	0.905
FTHM	0.905
NDLS	0.904
ADPT	0.903
NEOG	0.903
EHTH	0.903

10 Most Negative Correlations
LPCN	-0.861
EML	-0.861
ESTA	-0.856
NHTC	-0.856
TAYD	-0.855
KRUS	-0.853
BSCO	-0.85
IVCB	-0.85
KEQU	-0.846
GHRS	-0.843

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Moleculin Biotech Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2023
Revenue:	$0
Gross Profit:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2022
Revenue:	$0
Gross Profit:	$-222 000 (0.00 %)
EPS:	$-14.37

FY	2021
Revenue:	$0.00
Gross Profit:	$-164 000 (0.00 %)
EPS:	$-1.614

Financial Reports:

No articles found.

Moleculin Biotech Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.